Abiopharma

🔍 Boyle James M (Executive)

Company: Medline Inc. (MDLN)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Acquired 764,252 shares of Incentive Units of Medline Holdings, LP at $16.49 per share (Derivative)
  Date: 2026-08-19 | Code: A | equity_swap_involved: false | shares_owned_after: 764,252.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2

Footnotes:

• F1: Represents performance-based incentive units of Medline Holdings, LP ("Incentive Units"), that were earned as a result of the achievement of certain performance criteria as certified by the compensation committee of the Issuer's board of directors on August 19, 2026. These Incentive Units are fully vested.
• F2: Incentive Units are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.
• F3: (Continued from Footnote 2 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.